debt_leverage_profile
Micro-cap penny stock; minimal long-term debt, near-zero leverage. A 200bps rate rise has negligible direct debt-service impact but raises equity financing cost materially.
Inferred
Agent_Inference
interest_rate_sensitivity
Primarily equity-funded; interest rate sensitivity is indirect via higher discount rates compressing speculative micro-cap valuations rather than debt-service pressure.
Inferred
Agent_Inference
geopolitical_supply_exposure
Low intensity; China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
supply_chain_dependency
Top chokepoints: (1) Southeast Asian botanical/extract sourcing hubs (Thailand, Indonesia); (2) Chinese API/nutraceutical ingredient manufacturing concentration.
Inferred
Agent_Inference
international_expansion_readiness
Revenues appear predominantly North American; international currency devaluation exposure is minimal currently but limits diversification optionality.
Inferred
Agent_Inference
geographic_footprint
Operations concentrated in North America; limited direct sovereign currency exposure; nascent international footprint reduces devaluation risk but also caps global upside.
Inferred
Agent_Inference
commodity_exposure_profile
Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
vendor_lock_dependency_score
High dependency risk: key botanical extract suppliers likely represent >30% of COGS; substitution requires costly reformulation and regulatory re-validation.
Inferred
Agent_Inference
business_model_type_primary
Physical product manufacturer/distributor of nutraceutical extracts; cloud dependency is low — account termination causes operational disruption but not existential failure.
Inferred
Agent_Inference
business_model_type_secondary
Secondary digital/e-commerce channel could face 30-day disruption; recovery feasible via alternative hosting, but order management and DTC revenue would be temporarily impaired.
Inferred
Agent_Inference
switching_cost_profile
Low API coupling risk; business is predominantly physical-product-based with limited deep software/API integrations; switching costs for digital tools are minimal.
Inferred
Agent_Inference
howey_test_risk_index
Primary revenue from product sales (nutraceutical extracts); does not meet Howey Test — no investment contract, profit expectation from others' efforts. Securities risk: low.
Inferred
Agent_Inference
regulatory_burden_tier
Very High
Medium
GICS-regulatory-overlay-v1
data_sovereignty_risk
Limited consumer PII collection typical of B2B ingredient supplier; GDPR/CCPA exposure is low-to-moderate depending on DTC e-commerce scale and email marketing practices.
Inferred
Agent_Inference
antitrust_exposure_flag
Micro-cap niche nutraceutical supplier; negligible market share precludes meaningful antitrust scrutiny. Risk rating: very low.
Inferred
Agent_Inference
regulatory_exposure_profile
Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.
Medium
GICS-regulatory-overlay-v1
revenue_model_type
Predominantly transactional product sales; recurring revenue likely <20% via repeat B2B purchase orders; no formal subscription or multi-year contract structure evident.
Inferred
Agent_Inference
monetization_vector
Direct product sales of botanical/nutraceutical extracts to B2B buyers and DTC consumers; margin dependent on commodity input costs and brand premium.
Inferred
Agent_Inference
pricing_architecture
Commodity-adjacent pricing with modest brand premium; vulnerable to input cost spikes and private-label substitution; limited contractual price protection mechanisms.
Inferred
Agent_Inference
pricing_power_rating
Low-to-moderate; nutraceutical extract market is competitive with many substitutes; brand differentiation and efficacy claims are primary but fragile pricing levers.
Inferred
Agent_Inference
target_gross_margin_bracket
53.7% Gross Margin (Strong (40-60%))
High
SEC-XBRL
churn_vulnerability_index
Free-rider risk is low; product is physical and transactional. Churn vulnerability stems from retailer/distributor shelf-space competition and consumer brand switching.
Inferred
Agent_Inference
headcount_cost_structure
Revenue growth is moderately headcount-linear; manufacturing and QA scale require proportional staffing, though distribution partnerships can absorb some volume growth.
Inferred
Agent_Inference
marginal_cost_of_growth
Sublinear growth possible via third-party contract manufacturing and distribution partnerships, but COGS scale nearly linearly; gross margin expansion limited without volume pricing.
Inferred
Agent_Inference
franchise_compliance_risk
No franchise network identified; not applicable.
Inferred
Agent_Inference
customer_acquisition_metric
At 10x scale, CAC likely rises as addressable niche saturates; unit economics depend on gross margin expansion via volume purchasing — currently thin at ~30-40% gross margin.
Inferred
Agent_Inference
network_effect_present
No meaningful network effects; nutraceutical product sales are non-networked. Repeat purchase loyalty is relationship/quality-driven, not structurally self-reinforcing.
Inferred
Agent_Inference
asset_efficiency_ratio
AI displacement risk is low for core operations; AI could optimize formulation R&D and marketing, but physical extraction/manufacturing is not immediately AI-displaceable.
Inferred
Agent_Inference
recession_resistance_tier
Moderate vulnerability; health/wellness supplements show some consumer trading-down pressure in recessions, though functional health focus provides partial defensibility.
Inferred
Agent_Inference
customer_segment_primary
B2B nutraceutical brands, supplement manufacturers, and private-label buyers seeking botanical extract ingredients; concentration risk if top 2-3 accounts represent >40% of revenue.
Inferred
Agent_Inference
customer_segment_secondary
DTC health-conscious consumers via e-commerce; fragmented segment reduces concentration risk but increases CAC and churn exposure relative to B2B contracts.
Inferred
Agent_Inference
characteristic_occupations
["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]
High
SOC-2018/GICS-overlay
agent_automatable_labor_share
0.32 (HIL — ~32% of characteristic roles agent-automatable)
Medium
SOC-2018 + agentic-exposure-v1
capital_expenditure_profile
0.0% CapEx / Revenue (Low-CapEx Asset-Light)
High
SEC-XBRL
sec_cik
0001630176
High
SEC-EDGAR
ticker
HYEX
High
SEC-EDGAR